A Multicenter, Prospective and Single-arm Clinical Study on the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma (R/R PTCL) With Chidamide and Duvalisib
Latest Information Update: 25 Feb 2025
At a glance
- Drugs Duvelisib (Primary) ; Tucidinostat (Primary)
- Indications Peripheral T-cell lymphoma
- Focus Therapeutic Use
Most Recent Events
- 19 Feb 2025 Planned End Date changed from 25 Dec 2025 to 25 Dec 2027.
- 19 Feb 2025 Planned primary completion date changed from 31 Dec 2024 to 31 Dec 2026.
- 04 Dec 2023 New trial record